Disease · MONDO_0017255

panuveitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. panuveitis. Diseases, record MONDO_0017255. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0017255

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: panuveitis; Open Targets
Open Targets ID: MONDO_0017255; Open Targets
Other names: diffuse uveitis, panuveitis (disease), total uveitis; Open Targets
Disease Ontology: DOID:12030; Disease Ontology
MeSH: D015864; MeSH
NCI Thesaurus: C84989; NCI Thesaurus
Orphanet: ORPHA:280898; Orphanet
Highest stage of its drugs: Approval, for 1 of its 8 drugs, from PMDA; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ADALIMUMAB	CHEMBL1201580	Antibody	Approval	PMDA	6	5	5	Drugs and targets
SECUKINUMAB	CHEMBL1743068	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DIFLUPREDNATE	CHEMBL1201749	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ENVUDEUCITINIB	CHEMBL5415395	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
SOTRASTAURIN	CHEMBL565612	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
IL12A	Interleukin-12	1	Interleukin-12 inhibitor	Phase 2	https://conductscience.org/library/genes/3592	Drugs and targets
IL12B	Interleukin-12	1	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Phase 2	https://conductscience.org/library/genes/3593	Drugs and targets
IL17A	Interleukin-17A	1	Interleukin 17A inhibitor	Phase 3	https://conductscience.org/library/genes/3605	Drugs and targets
IL23A	Interleukin-23	1	Interleukin-23 inhibitor	Phase 2	https://conductscience.org/library/genes/51561	Drugs and targets
PRKCA	Protein kinase C (PKC)	1	Protein kinase C (PKC) inhibitor	Phase 2	https://conductscience.org/library/genes/5578	Drugs and targets
PRKCB	Protein kinase C (PKC)	1	Protein kinase C (PKC) inhibitor	Phase 2	https://conductscience.org/library/genes/5579	Drugs and targets
PRKCD	Protein kinase C (PKC)	1	Protein kinase C (PKC) inhibitor	Phase 2	https://conductscience.org/library/genes/5580	Drugs and targets
PRKCE	Protein kinase C (PKC)	1	Protein kinase C (PKC) inhibitor	Phase 2	https://conductscience.org/library/genes/5581	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01148225	A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis	Phase 3	424	2019-04-04	Uveitis	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01124838	Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis	Phase 3	261	2016-06-21	Uveitis	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01138657	Efficacy and Safety of Adalimumab in Patients With Active Uveitis	Phase 3	239	2016-08-22	Uveitis	ADALIMUMAB, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT01032915	Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis	Phase 3	125	2015-11-05	Non-infectious Uveitis	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT01093846	38 Week Extension Study to CAIN457C2303	Phase 3	59	2016-02-22	Uveitis	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT01095250	Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis	Phase 3	30	2015-11-03	Uveitis	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02911116	Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)	Phase 2	8	2021-03-26	Uveitis	USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT01314417	Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate	Phase 1/2	2	2013-09-26	Non-infectious Intermediate and Posterior Uveitis	METHOTREXATE	Its record names the disease	ClinicalTrials.gov
NCT05105347	Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis	Phase 4	130		Uveitis	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT04588818	Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis	Phase 2	30		Uveitis	ADALIMUMAB, METHOTREXATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Adalimumab vs Placebo: serious adverse events	8 of 131	10 of 130	261	NCT01124838	Trial comparisons
Adalimumab vs Placebo: serious adverse events	16 of 119	5 of 120	239	NCT01138657	Trial comparisons
Cohort 1 (Subcutaneous Only) vs Cohort 2 (IV and Subcutaneous): deaths from any cause	0 of 5	0 of 3	8	NCT02911116	Trial comparisons
Cohort 1 (Subcutaneous Only) vs Cohort 2 (IV and Subcutaneous): serious adverse events	0 of 5	0 of 3	8	NCT02911116	Trial comparisons
Cohort 1 (Subcutaneous Only) vs Cohort 2 (IV and Subcutaneous): Proportion of Participants With ≥15 Letter Loss at Any Follow-up Visit.	1 of 4	0 of 2	6	NCT02911116	Trial comparisons
Cohort 1 (Subcutaneous Only) vs Cohort 2 (IV and Subcutaneous): Ability to Taper Concomitant Immunosuppressive Medications	1 of 4	0 of 2	6	NCT02911116	Trial comparisons
Cohort 1 (Subcutaneous Only) vs Cohort 2 (IV and Subcutaneous): Number of Participants Experiencing a Treatment Response by Week 16	4 of 4	2 of 2	6	NCT02911116	Trial comparisons
Cohort 1 (Subcutaneous Only) vs Cohort 2 (IV and Subcutaneous): Number of Participants Experiencing a Clinically Significant Increase in Elevated Intraocular Pressure (IOP) at Any Follow-up Visit	2 of 4	0 of 2	6	NCT02911116	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38782788	RESULT	1	PubMed
34864108	RESULT	1	PubMed
33157077	RESULT	1	PubMed
27602665	RESULT	1	PubMed
37172782	DERIVED	1	PubMed
28426849	DERIVED	2	PubMed
28237411	DERIVED	1	PubMed
23290985	DERIVED	2	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0017255

GET https://conductscience.org/api/diseases/v1/MONDO_0017255/drugs

API reference For AI assistants